Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. (NCT00769886), a randomized phase 3 study. The primary outcome is Ocular Itching.

2. Clinical Question

The primary measure was itching at 3, 5, and 7 minutes after challenge at 14 days. Itching was rated on a 0–4 numerical analog scale, with 0.5-unit increments allowed. The record describes 0.0 as no itching and 4.0 as incapacitating itch with an irresistible urge to rub.

The registry record identifies the study as a phase 3 trial and reports that it is completed. However, it does not report the group-level itching results, comparisons between groups, or estimates of treatment effects. Therefore, the clinical question can be described from the design and endpoint, but the posted information does not show how the groups differed on the primary measure.

3. Trial Design

This was a multicenter, randomized, double-masked, parallel-group phase 3 study. Its stated purpose was to evaluate the onset and duration of action of KetoNaph in a conjunctival allergen challenge model of acute allergic conjunctivitis, with vehicle and active-component comparison groups. Random assignment is intended to distribute participant characteristics across groups without selecting treatment according to those characteristics. Double masking is intended to reduce the influence of treatment knowledge on participants’ assessments and study conduct. The record does not describe how randomization or masking was implemented.

The four groups were KetoNaph, ketotifen, naphazoline, and vehicle. The registry record reports enrollment of 144 participants. Its safety summaries list 36 participants at risk in the KetoNaph group, 36 in the ketotifen group, 35 in the naphazoline group, and 37 in the vehicle group. Those safety counts describe the denominators used for the posted adverse-event summaries; the record does not give a fuller account of treatment assignment or analysis populations.

The trial used an induced challenge model rather than reporting outcomes during ordinary day-to-day exposure. The primary itching assessments were scheduled at 3, 5, and 7 minutes after challenge at 14 days. This arrangement focuses the question on responses during a defined period after allergen exposure. It does not, by itself, establish how results would translate to other settings or symptom patterns.

The registry record says the trial is completed. It does not report the protocol details needed to reconstruct the full design, including the intended treatment schedule, the method for determining challenge response, or the planned statistical comparison. Such details should not be inferred from the intervention names or endpoint description.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Ocular Itching, measured over 3, 5, and 7 minutes post challenge at 14 days.

The primary endpoint was ocular itching, rated by the participant after conjunctival allergen challenge. Itching is a symptom experienced by the participant, so a participant rating captures a different aspect of the response from an observer-assessed sign such as redness or swelling. The scale ran from 0.0, meaning no itching, to 4.0, meaning incapacitating itch with an irresistible urge to rub. Ratings could use 0.5-unit increments, but not 0.25-unit increments.

Assessments were made at 3, 5, and 7 minutes post challenge at 14 days. Multiple early assessments can describe the symptom response across the scheduled post-challenge period, rather than at a single instant. The registry record does not state how the three ratings were combined, whether each time point was treated as a separate primary analysis, or what summary measure was used for a treatment comparison. It identifies the endpoint parameter as a mean and its dispersion as a standard deviation, but does not provide the resulting group means or standard deviations.

As a general statistical point, the mean describes the average rating, while the standard deviation describes how spread out individual ratings are around that average. Neither measure alone shows the full shape of a rating distribution. With no reported endpoint estimates or comparisons, the posted information describes how itching was measured but does not establish the size or precision of any group difference.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record labels the primary outcome as a continuous measure summarized by a mean and standard deviation. A numerical analog rating is not a count of events: it assigns a value along an ordered scale of symptom intensity. Summarizing such ratings with a mean conveys an average level, while the standard deviation describes variation among ratings. These summaries are useful for comparing group averages, but interpretation also depends on how many participants contributed data and how the ratings were distributed. The record does not include the group summaries or the number contributing to each primary assessment.

General statistical explanation: a treatment comparison may be expressed as a difference between group means. The direction of that difference depends on the order in which the groups are compared and on the scale’s meaning. For this scale, higher values correspond to more severe itching, as the endpoints are defined from no itching to incapacitating itch. An estimate should be read together with its uncertainty, not in isolation. No mean difference or uncertainty interval for the primary outcome is reported in the registry record.

The three scheduled assessments matter to interpretation. A separate comparison at each time point answers a time-specific question; a combined summary would answer a different question and would require a defined rule for combining observations. Repeated ratings from the same participant are related rather than independent observations. General statistical methods for repeated measurements account for that within-participant relationship, or otherwise specify how repeated ratings are summarized. The registry record does not say whether the time points were analyzed separately, jointly, or through a summary, and no model is reported.

Randomization supports comparisons between assigned groups because, in expectation, it reduces systematic differences in participant characteristics at the outset. It does not guarantee that every group will be identical, and it does not eliminate the need to report the analysis population and handling of missing observations. The study is described as randomized and double-masked, but the record does not specify the randomization procedure, allocation concealment, masking procedures, or whether analysis followed assigned treatment. Those details are not reported in the registry record.

General statistical explanation: a confidence interval communicates uncertainty around an estimate. A narrow interval indicates greater precision under the model and data used; a wide interval indicates less precision. An interval that includes values in different directions or values of meaningfully different sizes can leave the result uncertain. A p-value alone would not describe the range of plausible effects. Since the registry record contains no primary-outcome estimate, interval, or p-value, none of these features can be assessed for this trial from the posted results.

The number of participants enrolled is not itself a measure of the precision of the primary comparison. Precision also depends on the number of participants with usable outcome data, the variation in their ratings, the comparison being made, and the analysis method. The registry record reports enrollment of 144 and safety denominators by group, but it does not report primary-outcome denominators or variability. No conclusion about primary-outcome precision follows from the total enrollment alone.

The record includes a general description of a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two groups, and a normal approximation. It does not report the numerical planning results in the registry record for this analysis, nor does it describe those assumptions as the trial’s original design justification. Such planning illustrations are not observed power and cannot replace effect estimates or confidence intervals. The registry record does not report the trial’s own sample-size justification.

General statistical explanation: over-dispersion means that observed variability is greater than a statistical model expects. When it occurs, a model that understates variability can make uncertainty appear smaller than it is. The appropriate variance model depends on the data and analysis; the registry record does not identify a fitted model or report a dispersion assessment. This concept is relevant to statistical interpretation in general, but there is no evidence in the registry record that over-dispersion was present or that a particular correction was used.

Finally, statistical significance and practical importance are different questions. A result can be estimated precisely yet have a small magnitude, or estimated imprecisely despite a potentially important magnitude. Evaluating either requires reported estimates and their uncertainty, interpreted in the context of the endpoint. Since the primary estimates are not reported in the registry record, those judgments cannot be made from the posted information.

10. Multiplicity, Missing Data and Analysis Populations

The primary endpoint was assessed at 3, 5, and 7 minutes after challenge at 14 days. The study also names secondary outcomes covering redness, chemosis, eyelid swelling, tearing, and ocular mucus drainage, and compares four treatment groups. Multiple time points, outcomes, or treatment contrasts can create multiplicity: the more statistical questions examined, the greater the chance that at least one appears noteworthy by chance if each is judged independently.

General statistical explanation: multiplicity can be addressed by defining a hierarchy of primary and secondary questions, adjusting significance thresholds, using simultaneous intervals, or treating secondary analyses as exploratory. The appropriate approach depends on the planned claims and analysis. The registry record does not report a multiplicity strategy, the statistical analysis plan, or results from analyses. It is therefore not possible to determine whether any adjustment was planned or applied.

Missing-data handling is also not reported in the registry record. The record does not state how missing itching ratings, incomplete follow-up, or participants who did not complete a scheduled assessment were handled. It does not identify an analysis population, explain exclusions, or report the number of participants with evaluable data at each time point. Safety denominators do not establish the denominators for the efficacy endpoint.

These omissions matter because an analysis based on only observed ratings can differ from one using methods that make explicit assumptions about missing observations. The record does not describe whether missingness was assessed or what assumptions, if any, informed the analysis. No particular procedure should be presumed. The registry record reports zero analyses, so it offers no evidence about how multiplicity or missing data were addressed in the trial’s statistical results.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

The registry record lists zero serious adverse events among participants at risk in each group: 36 for KetoNaph, 36 for ketotifen, 35 for naphazoline, and 37 for vehicle. It also lists zero participants affected by other adverse events in each of those groups. No serious adverse-event terms are listed.

These are the posted counts, not evidence that an event is impossible or that the groups have identical safety profiles. A zero count means no affected participants are recorded in that category for the stated group denominator. It does not establish the absence of events that were not captured, not reported, or outside the registry’s summary.

Death counts are not reported in the registry record; the death entries are not numerical zeroes. The record also does not describe adverse-event collection methods, duration of safety follow-up, event definitions, or statistical comparisons. The counts should therefore be read as a limited descriptive summary, not as a comparative safety analysis or as a basis for conclusions about clinical use.

12. What the Result Does, and Does Not, Mean

The trial record establishes that a randomized, double-masked, parallel-group study was conducted in a conjunctival allergen challenge model, with a combination ophthalmic solution, its individual components, and vehicle as groups. It defines participant-rated itching as the primary outcome and specifies the scale and assessment times. This is useful information about the question the study was designed to examine.

The record does not report the primary outcome results. It therefore does not show whether itching ratings differed across groups, how large any difference was, or how precisely it was estimated. It also does not report results for the named secondary outcomes. The completed status and phase designation do not answer these questions. Neither the treatment names nor the study’s stated purpose can substitute for observed comparative results.

General statistical explanation: a treatment effect is interpreted through both its estimate and its uncertainty, alongside the outcome definition and the population studied. When these results are absent, a claim of benefit, no effect, equivalence, or harm cannot be supported by the registry results. Lack of a reported comparison is not a finding that the groups were the same.

The model is specifically described as conjunctival allergen challenge-induced acute allergic conjunctivitis. The record does not establish that results from this setting would apply to other circumstances. More broadly, conclusions about clinical meaning would require the outcome estimates, analysis details, safety context, and information about the participants and follow-up. Those details are not reported in the registry record. The defensible conclusion is that the registry describes the study design and measurement approach, but not the comparative outcome evidence needed to interpret treatment effects.

13. Why This Trial Matters Statistically

This study illustrates an important distinction in trial reporting: a detailed design description is not the same as a report of results. The registry identifies randomization, masking, a parallel-group model, four groups, the primary symptom measure, and its timing. These elements allow readers to understand the planned comparison. Yet without group results and an analysis, the treatment question remains unanswered by the posted record.

The endpoint also highlights the value of specifying measurement details. The 0–4 itching scale, permitted 0.5-unit increments, and post-challenge assessment times clarify what a rating means and when it was made. Those details are essential for interpreting any estimate that might be reported. However, the endpoint definition alone cannot tell readers whether the groups differed or whether an observed difference would be precise.

Several features needed for statistical appraisal are absent: primary estimates, uncertainty measures, the analysis model, analysis populations, missing-data methods, and any multiplicity strategy. Their absence prevents assessment of the strength and robustness of comparative findings. The safety summary is similarly limited to descriptive counts, without information about ascertainment or comparative analyses.

Statistically, the record is a reminder that enrollment and study completion do not convey the effect size or evidential strength. Transparent reporting of estimates, uncertainty, denominators, and analysis decisions is needed to connect a randomized design to an interpretable result. For this trial, the registry record documents the question and basic structure, while leaving those key comparative findings unreported.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation of the registry record is that it contains no primary-outcome analyses or numerical efficacy results. There are no reported group means or standard deviations for ocular itching, no treatment contrasts, and no confidence intervals or p-values. The record therefore cannot support a quantitative interpretation of the primary comparison.

Although the outcome schedule includes assessments at 3, 5, and 7 minutes after challenge at 14 days, the record does not explain how those repeated measurements were handled. It does not state whether each time point was analyzed separately, whether a combined measure was used, or how within-participant dependence was addressed. The registry record also does not describe the statistical analysis plan, multiplicity control, analysis populations, or missing-data methods.

Generalizability is constrained by the described setting: the study used a conjunctival allergen challenge model of acute allergic conjunctivitis. The record does not give enough information to characterize the participants beyond the condition, nor does it report details that would support comparisons with other populations or settings. It also does not provide the treatment schedule or broader follow-up information needed to interpret the duration of observation.

The safety summary lists no affected participants for serious or other adverse events in the stated group denominators, but it does not describe collection methods or the scope of monitoring. Death counts are not reported in the registry record. These limitations are limits of what the posted record establishes; they should not be replaced with assumptions about the unreported protocol or results.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. — NCT00769886.
• Registry record last updated 2024-04-03; status last verified 2020-10.
• Results first posted 2020-10-27.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed phase 3, multicenter, randomized, double-masked, parallel-group trial of KetoNaph in a conjunctival allergen challenge model of acute allergic conjunctivitis. Enrollment was 144. The four groups were KetoNaph, ketotifen, naphazoline, and vehicle.

The primary outcome was participant-rated ocular itching on a 0–4 scale, assessed at 3, 5, and 7 minutes post challenge at 14 days. The registry record names secondary outcomes involving ocular redness, swelling, tearing, and mucus drainage. It reports zero serious and zero other adverse events in the listed group denominators, while death counts are not reported in the registry record.

No primary-outcome results, comparative estimates, or statistical analyses are reported. The record describes the trial’s question and measurement approach but does not provide the results needed to judge treatment differences or their precision.